Toronto/CMEDIA: Coverage of Trikafta, the latest treatment option for cystic fibrosis, has been expanded by the Ontario government o include all Ontarians aged six and over through its publicly-funded drug program.
The province is also changing the eligibility criteria to remove the measurement of patients’ lung function in order to further reduce barriers for cystic fibrosis patients to access life-changing treatments.
Sylvia Jones, Deputy Premier and Minister of Health was reported to say in a news release that expanding coverage will ensure not only be beneficial to children with cystic fibrosis through this innovative, life-changing treatment sooner but also provide patients with more options for treatment leading to a stronger health care system for all Ontarians.
Following new recommendations by the Canadian Agency for Drugs and Technology in Health (CADTH), treatment which was only available to Ontarians aged 12, Ontario is now the first province to expand access to youth aged six to 11 and over.
To help determine if Trikafta is the right treatment option for Ontarians, eligible patients, and their families should reach out to their health care team.
“Today’s news will change the trajectory of the disease and the future for many children and adults in Ontario who live with cystic fibrosis…by expanding coverage of Trikafta to include children ages six to 11 years old…restrictive start criterion has also been removed, enabling more people to access the drug. We celebrate this news alongside our CF community in Ontario, who has worked tirelessly for this day,” said Kelly Grover, President, and CEO, of Cystic Fibrosis Canada.
#Ontario; #CysticFibrosis
